^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABL102

    i
    Other names: ABL102, ABL 102, ABL-102
    Associations

    News

    Trials
    Company:
    ABL Bio
    Drug class:
    CD137 agonist, ROR1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    ROR1 targeted 4-1BB costimulatory bispecific antibody, ABL102, exhibits potent in vitro and vivo antitumor activity and superior safety profile (AACR 2023)
    In conclusion, ABL102 exhibited potent in vitro and vivo anti-tumor activity and it was well tolerated and safe in the NHP toxicity study. These results strongly suggest that ABL102 is promising therapeutics for ROR1 positive cancer patients.
    Preclinical
    |
    IFNG (Interferon, gamma) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    ROR1 expression • ROR1 positive
    |
    ABL102